Deciphera Pharmaceuticals LLC

DCPH

NASDAQ. Currency in USD

14.85 -0.46 ( -3.00% )

Real time prices: December 19

Market Cap.
1.00B
Beta (5Y monthly)
0.75
Price/Earnings
-
EPS (TTM)
-3.46
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
574,428
1y Target Est.
18.65
Day's Range
14.62
-
15.29
52 Week's Range
6.51
-
20.88

Historical Summary

Performance
EPS growth
Share Buybacks

About Deciphera Pharmaceuticals LLC

Sector
Healthcare
Industry
Biotechnology
Website
https://www.deciphera.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
58.48M
Employees
280
Address
200 Smith Street, Waltham, MA, United States, 02451
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Latest news

Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies

Needham has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ: THRX) with a Buy rating and...
By Benzinga - 6 weeks ago

Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat...
By Zacks Investment Research - 12 weeks ago

Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?

Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to...
By Zacks Investment Research - 14 weeks ago

Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?

Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer...
By Zacks Investment Research - 16 weeks ago

Is Deciphera Pharmaceuticals (DCPH) Stock Outpacing Its Medical Peers This Year?
Is Deciphera Pharmaceuticals (DCPH) Stock Outpacing Its Medical Peers This Year?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Jazz Pharmaceuticals (JAZZ) have performed compared to...
By Zacks Investment Research - 16 weeks ago

Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since...
By Zacks Investment Research - 17 weeks ago